Diagnostic accuracy of a three-protein signature in women with suspicious breast lesions: a multicenter prospective trial

[1]  W. Han,et al.  Diagnostic performance improvement with combined use of proteomics biomarker assay and breast ultrasound , 2021, Breast Cancer Research and Treatment.

[2]  Z. Fan,et al.  Non-Invasive Biomarkers for Early Detection of Breast Cancer , 2020, Cancers.

[3]  S. Duffy,et al.  Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial , 2020, The Lancet. Oncology.

[4]  Se Kyung Lee,et al.  Breast Cancer Statistics in Korea in 2017: Data from a Breast Cancer Registry , 2020, Journal of breast cancer.

[5]  W. Han,et al.  Efficacy of Mastocheck for Screening of Early Breast Cancer: Comparison with Screening Mammography , 2019 .

[6]  W. Han,et al.  A Validation Study of a Multiple Reaction Monitoring-Based Proteomic Assay to Diagnose Breast Cancer , 2019, Journal of breast cancer.

[7]  Yinglong Hou,et al.  Carbonic Anhydrase 1-Mediated Calcification Is Associated With Atherosclerosis, and Methazolamide Alleviates Its Pathogenesis , 2019, Front. Pharmacol..

[8]  Cristina Núñez.  Blood-based protein biomarkers in breast cancer. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[9]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[10]  M. Esteller,et al.  CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer , 2017, Oncotarget.

[11]  Jiaxiang Wang,et al.  Identification of Apolipoprotein C-I Peptides as a Potential Biomarker and its Biological Roles in Breast Cancer , 2016, Medical science monitor : international medical journal of experimental and clinical research.

[12]  S. Choi,et al.  Development and Validation of a Novel Plasma Protein Signature for Breast Cancer Diagnosis by Using Multiple Reaction Monitoring-based Mass Spectrometry. , 2015, Anticancer research.

[13]  Gillian D Sanders,et al.  Benefits and Harms of Breast Cancer Screening: A Systematic Review. , 2015, JAMA.

[14]  X. Chang,et al.  CA1 contributes to microcalcification and tumourigenesis in breast cancer , 2015, BMC Cancer.

[15]  K. Straif,et al.  Breast-cancer screening--viewpoint of the IARC Working Group. , 2015, The New England journal of medicine.

[16]  Cecilia L Mercado,et al.  BI-RADS update. , 2014, Radiologic clinics of North America.

[17]  D. Noh,et al.  Comparative profiling of plasma proteome from breast cancer patients reveals thrombospondin-1 and BRWD3 as serological biomarkers , 2011, Experimental & Molecular Medicine.

[18]  D. Noh,et al.  Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker , 2010, BMC Cancer.

[19]  M. Duffy,et al.  Serum tumor markers in breast cancer: are they of clinical value? , 2006, Clinical chemistry.

[20]  J. Spangler,et al.  Reported pain following mammography screening. , 2003, Archives of internal medicine.

[21]  D. Noh,et al.  Proteomic analysis of breast cancer tissue reveals upregulation of actin‐remodeling proteins and its relevance to cancer invasiveness , 2009, Proteomics. Clinical applications.

[22]  D. Noh,et al.  Identification of circulating endorepellin LG3 fragment: Potential use as a serological biomarker for breast cancer , 2008, Proteomics. Clinical applications.

[23]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..